Last reviewed · How we verify

Placebo + Prolonged Imaginal Exposure — Competitive Intelligence Brief

Placebo + Prolonged Imaginal Exposure (Placebo + Prolonged Imaginal Exposure) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Psychiatry/Mental Health.

phase 3 Psychiatry/Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Placebo + Prolonged Imaginal Exposure (Placebo + Prolonged Imaginal Exposure) — Weill Medical College of Cornell University. Placebo combined with prolonged imaginal exposure therapy leverages psychological habituation to trauma memories through repeated, extended mental reliving of traumatic events.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo + Prolonged Imaginal Exposure TARGET Placebo + Prolonged Imaginal Exposure Weill Medical College of Cornell University phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo + Prolonged Imaginal Exposure — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-prolonged-imaginal-exposure. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: